PT  - JOURNAL ARTICLE
AU  - Heba Ijaz
AU  - Mateusz Koptyra
AU  - Krutika S. Gaonkar
AU  - Jo Lynne Rokita
AU  - Valerie P. Baubet
AU  - Lamiya Tauhid
AU  - Yankun Zhu
AU  - Miguel Brown
AU  - Gonzalo Lopez
AU  - Bo Zhang
AU  - Sharon J. Diskin
AU  - Zalman Vaksman
AU  - Children’s Brain Tumor Tissue Consortium
AU  - Jennifer L. Mason
AU  - Elizabeth Appert
AU  - Jena Lilly
AU  - Rishi Lulla
AU  - Thomas De Raedt
AU  - Allison P. Heath
AU  - Alex Felmeister
AU  - Pichai Raman
AU  - Javad Nazarian
AU  - Maria Rita Santi
AU  - Phillip B. Storm
AU  - Adam Resnick
AU  - Angela J. Waanders
AU  - Kristina A. Cole
TI  - Pediatric High Grade Glioma Resources From the Children’s Brain Tumor Tissue Consortium (CBTTC) and Pediatric Brain Tumor Atlas (PBTA)
AID  - 10.1101/656587
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 656587
4099  - http://biorxiv.org/content/early/2019/05/31/656587.short
4100  - http://biorxiv.org/content/early/2019/05/31/656587.full
AB  - Background Pediatric high grade glioma (pHGG) remains a fatal disease. Increased access to richly annotated biospecimens and patient derived tumor models will accelerate pHGG research and support translation of research discoveries. This work describes the pediatric high grade glioma set of the Children’s Brain Tumor Tissue Consortium (CBTTC) from the first release (October 2018) of the Pediatric Brain Tumor Atlas (PBTA).Methods pHGG tumors with associated clinical data and imaging were prospectively collected through the CBTTC and analyzed as the Pediatric Brain Tumor Atlas (PBTA) with processed genomic data deposited into PedcBioPortal for broad access and visualization. Matched tumor was cultured to create high grade glioma cell lines analyzed by targeted and WGS and RNA-seq. A tissue microarray (TMA) of primary pHGG tumors was also created.Results The pHGG set included 87 collection events (73 patients, 60% at diagnosis, median age of 9 yrs, 55% female, 46% hemispheric). Analysis of somatic mutations and copy number alterations of known glioma genes were of expected distribution (36% H3.3, 47% TP53, 24% ATRX and 7% BRAF V600E variants). A pHGG TMA (n=77), includes 36 (53%) patient tumors with matched sequencing. At least one established glioma cell line was generated from 23 patients (32%). Unique reagents include those derived from a H3.3 G34R glioma and from tumors with mismatch repair deficiency.Conclusion The CBTTC and PBTA have created an openly available integrated resource of over 2,000 tumors, including a rich set of pHGG primary tumors, corresponding cell lines and archival fixed tissue to advance translational research for pHGG.IMPORTANCE OF STUDY High-grade gliomas (HGG) remain the leading cause of cancer death in children. Since molecularly heterogeneous, preclinical studies of pediatric HGG will be most informative if able to compare across groups. Given their relatively rarity, there are few readily available biospecimens and cellular models to inform preclinical laboratory and genomic translational research. Therefore, the aim of this CBTTC study was to highlight the panel of pediatric HGG cases whose primary tumors have undergone extensive genomic analysis, have clinical data, available imaging and additional biospecimens, including tumor, nucleic acids, cell lines and FFPE tissue on a tissue microarray (TMA).